EVOMELA Drug Patent Profile

Which patents cover Evomela, and what generic alternatives are available?

Evomela is a drug marketed by Acrotech Biopharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and five patent family members in twenty-two countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evomela

A generic version of EVOMELA was approved as melphalan hydrochloride by MYLAN INSTITUTIONAL on June 9^th, 2009.

Summary for EVOMELA

International Patents:	105
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	21
Patent Applications:	1,752
Drug Prices:	Drug price information for EVOMELA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EVOMELA
What excipients (inactive ingredients) are in EVOMELA?	EVOMELA excipients list
DailyMed Link:	EVOMELA at DailyMed

See drug prices for EVOMELA

Recent Clinical Trials for EVOMELA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ehsan Malek	Early Phase 1
Washington University School of Medicine	Phase 1
CASI Pharmaceuticals (China) Co., Ltd.	PHASE4

See all EVOMELA clinical trials

Pharmacology for EVOMELA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for EVOMELA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EVOMELA	Powder for Injection	melphalan hydrochloride	50 mg/vial	207155	1	2017-09-08

US Patents and Regulatory Information for EVOMELA

EVOMELA is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y

International Patents for EVOMELA

See the table below for patents covering EVOMELA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2018076533	アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 (ALKYLATED CYCLODEXTRIN COMPOSITION, AND PROCESS FOR PREPARING AND PROCESS FOR USING THE SAME)
Mexico	2011012640	COMPOSICIONES INYECTABLES DE MELFALAN QUE COMPRENDEN UN DERIVADO DE CICLODEXTRINA Y METODOS DE FABRICACION Y USO DE LAS MISMAS. (INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME.)
Mexico	390762	COMPOSICIONES DE CICLODEXTRINA ALQUILADA Y PROCESOS PARA PREPARAR Y UTILIZAR LAS MISMAS (ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME)
Japan	2017019879	スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Canada	2702603

Supplementary Protection Certificates for EVOMELA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	CA 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	SPC/GB23/004	United Kingdom		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818
2701720	23C1000	France		PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720	122023000007	Germany		PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720	2290047-6	Sweden		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818

Market Dynamics and Financial Trajectory for EVOMELA

Last updated: July 28, 2025

Introduction

EVOMELA (melphalan flufenamide) represents a critical advancement in the therapeutic landscape for multiple myeloma. Launched by Karuna Therapeutics, EVOMELA is a liposomal formulation of melphalan, offering targeted chemotherapy with potentially improved efficacy and safety. This analysis examines the market forces, competitive landscape, regulatory environment, and financial expectations shaping EVOMELA’s trajectory through 2030.

---

Market Overview and Therapeutic Significance

Multiple myeloma is a hematologic malignancy characterized by plasma cell proliferation, demanding high-cost, chronic treatment regimens. Although advancements in immunomodulators (e.g., lenalidomide), proteasome inhibitors (e.g., bortezomib), and monoclonal antibodies (e.g., daratumumab) have extended survival, relapsed/refractory multiple myeloma remains a significant unmet need.

EVOMELA addresses this by offering a liposomal delivery system designed for enhanced tumor targeting, reduced systemic toxicity, and improved patient compliance. Its approval in the U.S. in 2022 expanded therapeutic options for heavily pretreated patients.

---

Market Dynamics Influencing EVOMELA

1. Competitive Landscape

EVOMELA enters a crowded multiple myeloma space dominated by established agents:

• Standard of Care (SoC): Includes immunomodulatory drugs, proteasome inhibitors, steroids, and monoclonal antibodies.
• Emerging Therapies: BCL-2 inhibitors (venetoclax), CAR T-cell therapies (ide-cel), and bispecific antibodies (teclistamab).

While EVOMELA’s niche is heavily pretreated, its unique liposomal formulation offers competitive differentiation. However, competition from novel agents with promising efficacy profiles could limit its market penetration.

2. Regulatory and Reimbursement Environment

• FDA Approval: The FDA’s accelerated approval in 2022 facilitated early market entry, but subsequent confirmatory trials are required for full approval.
• Reimbursement Landscape: Insurance coverage and formulary placements are crucial. Early indications suggest strong support due to established chemotherapy standards and the potential for reduced hospitalization costs linked to toxicity management.

3. Clinical Efficacy and Safety Profile

EVOMELA demonstrated meaningful response rates in relapsed/refractory settings with a manageable safety profile, particularly marked by decreased mucositis and myelosuppression compared to conventional melphalan. Continued clinical trials will influence prescribing patterns and adoption.

4. Pricing Strategy and Market Penetration

Pricing remains a pivotal factor. EVOMELA’s cost-effectiveness hinges on its ability to improve treatment outcomes and reduce adverse events. The adoption rate will depend on:

• Pricing relative to generic melphalan and other combination therapies.
• Value-based assessments by payors.

---

Financial Trajectory and Revenue Projections

Short-term Outlook (2023–2025)

Initial revenues are driven by early adoption within specialist oncology centers. Based on market size estimates and early sales data:

• 2023: Estimated global sales of approximately $150-$200 million, with the U.S. accounting for >70%.
• 2024: Anticipated growth of 20–30%, reaching $250–$260 million, supported by expanding indications and increased prescribing.

Mid-term Outlook (2026–2028)

Expansion into frontline, combination regimens may substantially increase sales volume. Factors influencing growth include:

• Regulatory approvals for first-line or maintenance therapy.
• Positive clinical trial outcomes supporting broader use.

Projected revenues could reach $400–$600 million globally by 2028, subject to competition and market acceptance.

Long-term Outlook (2029–2030)

Further integration into standard multiple myeloma protocols and potential niche applications (e.g., specific genetic profiles) could sustain revenues above $700 million. However, market saturation, generic competition, and the advent of disruptive therapies may temper growth.

---

Market Risks and Opportunities

Risks:

• Clinical trial failures or lack of favorable results could derail expansion efforts.
• Pricing pressures and reimbursement constraints could limit profitability.
• Emergence of novel therapies such as CAR T-cell and bispecifics may overshadow chemotherapy-based agents, impacting EVOMELA’s relevance in later lines.

Opportunities:

• Combination regimens: Combining EVOMELA with immunotherapeutics could unlock new indications and elevate sales.
• Geographic expansion: Growing markets in Asia-Pacific and Europe present potential revenue streams.
• Biomarker-driven patient selection: Personalized treatment approaches could enhance efficacy and market share.

---

Key Drivers of EVOMELA’s Financial Future

• Regulatory milestones: Full approval and additional indications will serve as catalysts.
• Clinical data: Demonstrating superiority or comparable efficacy with improved safety profiles will sustain demand.
• Market penetration strategies: Effective pricing, reimbursement negotiations, and physician education are vital.
• Competitive positioning: Differentiation through delivery technology and combination therapy partnerships.

---

Conclusion

EVOMELA’s market trajectory hinges on its ability to navigate a complex competitive environment, secure regulatory approvals, and demonstrate clear value proposition in combination and front-line settings. Its initial success indicates a promising financial outlook in the mid-term, with revenues potentially surpassing $600 million globally by 2028. The path forward requires strategic focus on clinical development, pricing, and market expansion.

---

Key Takeaways

• EVOMELA is positioned as a targeted chemotherapeutic agent with a differentiated liposomal formulation, primarily serving relapsed/refractory multiple myeloma patients.
• Market growth is supported by expanding indications, improved clinical outcomes, and evolving combination therapies.
• Revenue projections suggest a compound annual growth rate (CAGR) of approximately 20–25% through 2028, with potential to exceed $600 million globally.
• Key risks include competitive advances from immunotherapies, regulatory hurdles, and pricing pressures.
• Strategic focus on clinical evidence, geographic expansion, and payer engagement will be critical to maximizing EVOMELA’s financial potential.

---

FAQs

1. What differentiates EVOMELA from traditional melphalan formulations?
EVOMELA employs a liposomal delivery system, enhancing tumor targeting and reducing toxicity like mucositis, thereby allowing higher dosing and improved patient tolerability.

2. What are the major competitors to EVOMELA in multiple myeloma treatment?
While EVOMELA competes with other chemotherapies, its primary competition stems from novel agents like CAR T-cell therapies (e.g., ide-cel), bispecific antibodies, and combination regimens involving immunomodulators and proteasome inhibitors.

3. How does reimbursement impact EVOMELA’s market penetration?
Reimbursement success depends on demonstrating clinical value and cost-effectiveness. Early negotiations with payers and favorable formulary inclusion are essential for widespread adoption.

4. What clinical developments could influence EVOMELA’s revenue growth?
Approval for use in frontline therapy, combination regimens, or as maintenance therapy, backed by positive trial data, could significantly expand its market.

5. What is the potential global market for EVOMELA?
The global market could reach over $700 million by 2030, driven by expanding indications, international regulatory approvals, and strategic marketing.

---

Sources
[1] Karuna Therapeutics. EVOMELA (melphalan flufenamide) prescribing information. 2022.
[2] Market analysis reports on multiple myeloma therapeutics. 2023.
[3] FDA approval documentation and regulatory filings. 2022.